SCHEMBL24253615

SCHEMBL24253615

N/C(=N\Nc1ccc(F)cc1)S(=O)(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 8/20 0.47
CA2 P00918 8/20 0.47
CA4 P22748 6/20 0.47
CA7 P43166 2/20 0.47
F2 P00734 3/20 0.45
PRSS1 P07477 3/20 0.45
PRSS2 P07478 3/20 0.45
PRSS3 P35030 3/20 0.45
ALDH1A1 P00352 3/20 0.44
CA9 Q16790 6/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 2/20 0.42
ALOX12 P18054 2/20 0.42
KMT2A Q03164 2/20 0.42
AHR P35869 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KDM4E B2RXH2 1/20 0.41
CA12 O43570 2/20 0.40
CACNA1B Q00975 1/20 0.38
APBA1 Q02410 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19463563 0.81 GAA (0.49) CA1CA2CA4CA7ALDH1A1
SCHEMBL19463562 0.81 GAA (0.49) CA1CA2CA4CA7ALDH1A1
SCHEMBL14701704 0.73 ALDH1A1 (0.46) CA1CA2CA4CA7F2
SCHEMBL12815704 0.70 ALDH1A1 (0.44) CA1CA2CA4CA7F2
SCHEMBL29047988 0.69 GAA (0.43) CA1CA2CA4CA7ALDH1A1
SCHEMBL15939608 0.69 ALDH1A1 (0.49) CA1CA2CA4CA7ALDH1A1
Sulfuric Acid SCHEMBL20984370 0.69 CA1 (0.50) CA1CA2CA4CA7F2
SCHEMBL18463191 0.69 ALDH1A1 (0.58) CA1CA2CA4CA7ALDH1A1
SCHEMBL518754 0.67 ALDH1A1 (0.51) CA1CA2CA4CA7ALDH1A1
Sulfuric Acid SCHEMBL28200868 0.66 F2 (0.48) CA1CA2CA4CA7F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
EP-4196478-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2023-06-21 EP disclosed
CN-116157404-A Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof 诺华股份有限公司 2023-05-23 CN disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 CA1 4190/4885CA2 1093/4885CA4 1356/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 CA1 4190/4885CA2 1093/4885CA4 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.